Neurocrine Acquires Wyeth’s Financial Interest in Indiplon
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 46 (Table of Contents)
Published: 4 Apr-2004
DOI: 10.3833/pdr.v2004.i46.815 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Neurocrine Biosciences entered into an agreement with Wyeth to acquire Wyeth’s financial interest worthing up to US$95 M in the late-stage insomnia treatment, indiplon...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS